ObsEva is a Swiss-based company dedicated to the development of innovative drugs for women’s reproductive medicine. ObsEva’s main focus is on therapies for preterm labor. ObsEva´s lead product is a clinical stage compound licensed from Merck Serono.


Team Member
more about
Jasper Bos
Latest News Entry
ObsEva to Present Pharmacology Results Demonstrating OBE022 Exerts a Synergistic Effect in Combination with Standard of Care in Animal Model for Preterm Labor
  • OBE022 is ObsEva's potential first-in-class, oral and selective PGF2alpha receptor antagonist -
all portfolio news